Vir Biotechnology (VIR) just unveiled an update. Sung Lee will depart from his role as Executive Vice President and CFO of Vir Biotechnology on May 3, 2024, to explore a
Vir Biotechnology (VIR) just unveiled an update. Sung Lee will depart from his role as Executive Vice President and CFO of Vir Biotechnology on May 3, 2024, to explore a
דיווח זה התקבל במסמך רשמי. המניות נמכרו ב-3 באפריל במחיר של 9.4577 דולר למניה.
In a regulatory filing, Vir Biotechnology CEO Marianne De Backer disclosed the sale of 72,995 common shares of the company on April 3 at a price of $9.4577 per share.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vir Biotechnology (VIR – Research Report) and IN8bio (INAB – Research Report) with bullish sentiments.
Vir Biotechnology (VIR)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, with a price target of $110.00. The company’s shares closed last Thursday at $10.52, close to its 52-week low of $7.72.
According to TipRanks.com, Trucchio ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Vir Biotechnology is a Strong Buy with an average price target of $32.00, representing a 196.0% upside. In a report issued on February 29, Goldman Sachs also maintained a Buy rating on the stock with a $28.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
IN8bio (INAB)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on IN8bio today and set a price target of $14.00. The company’s shares closed last Thursday at $1.16, close to its 52-week low of $0.65.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of
IN8bio has an analyst consensus of Strong Buy, with a price target consensus of $9.00, a 625.8% upside from current levels. In a report issued on March 12, JonesTrading also initiated coverage with a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VIR:
Analyst Roanna Ruiz of Leerink Partners maintained a Buy rating on Vir Biotechnology (VIR – Research Report), with a price target of $20.00. Roanna Ruiz has given his Buy rating